The effects of probiotics on gastrointestinal symptoms and microbiota in patients with celiac disease: a systematic review and meta-analysis on clinical trials.
Celiac disease
Celiac disease autoimmunity
Gut microbiota
Probiotics
Synbiotic
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
05
12
2022
accepted:
30
12
2022
medline:
2
10
2023
pubmed:
8
1
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
Gluten-free diet (GFD) is the most effective method to manage celiac disease (CD). Many patients do not reach the complete symptom alleviation, even by strict GFD. Recent studies have reported inconsistent results regarding the beneficial benefits of taking probiotics. Therefore, we aimed to evaluate the effects of probiotics on gastrointestinal (GI) symptoms and the possible underlying causes in CD and celiac disease autoimmunity (CDA) patients. Databases, including PubMed, Scopus, Embase, Web of Science and Google Scholar, were searched for clinical trials published until July 2022 about assessing the effects of probiotics or synbiotics on CD or CDA patients. We collected data on GI symptoms, CD markers, inflammatory and immune responses, adverse events, and gut microbiota. A random effect meta-analysis was used to estimate the pooled standardized mean difference (SMD) and confidence interval (CI). We screened 7234 articles, of which 14 were included in the qualitative analysis and 5 in the quantitative analysis. Probiotics might alleviate GI symptoms, especially in the highly symptomatic patients, and improve immune response in CD and CDA patients. Results of the meta-analysis showed that probiotics increased the abundance of Bifidobacterium (SMD: 0.72, 95%CI (0.13, 1.30) and Lactobacillus (SMD: 0.49, 95%CI (0.18, 0.80) as compared with placebo. Probiotics did not increase the adverse events compared to the placebo. Probiotics might alleviate GI symptoms and immune response and improve dysbiosis in CD and CDA patients. However, high-quality clinical trials are needed to increase the level of evidence. Also, the most suitable combination of probiotics is yet to find.
Identifiants
pubmed: 36609792
doi: 10.1007/s10238-022-00987-x
pii: 10.1007/s10238-022-00987-x
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2773-2788Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:823-836.e822. https://doi.org/10.1016/j.cgh.2017.06.037 .
doi: 10.1016/j.cgh.2017.06.037
pubmed: 29551598
Briani C, Samaroo D, Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev. 2008;7:644–50. https://doi.org/10.1016/j.autrev.2008.05.006 .
doi: 10.1016/j.autrev.2008.05.006
pubmed: 18589004
Parzanese I, Qehajaj D, Patrinicola F, et al. Celiac disease: from pathophysiology to treatment. World J Gastrointest Pathophysiol. 2017;8:27–38. https://doi.org/10.4291/wjgp.v8.i2.27 .
doi: 10.4291/wjgp.v8.i2.27
pubmed: 28573065
pmcid: 5437500
Palmieri O, Castellana S, Bevilacqua A, et al. Adherence to gluten-free diet restores alpha diversity in celiac people but the microbiome composition is different to healthy people. Nutrients. 2022. https://doi.org/10.3390/nu14122452 .
doi: 10.3390/nu14122452
pubmed: 36079864
pmcid: 9460686
Więch P, Chmiel Z, Bazaliński D, et al. The relationship between body composition and a gluten free diet in children with celiac disease. Nutrients. 2018. https://doi.org/10.3390/nu10111817 .
doi: 10.3390/nu10111817
pubmed: 30469383
pmcid: 6266332
Francavilla R, Cristofori F, Vacca M, Barone M, De Angelis M. Advances in understanding the potential therapeutic applications of gut microbiota and probiotic mediated therapies in celiac disease. Expert Rev Gastroenterol Hepatol. 2020;14:323–33. https://doi.org/10.1080/17474124.2020.1745630 .
doi: 10.1080/17474124.2020.1745630
pubmed: 32216476
Jedwab CF, Roston BCDMB, Toge ABFDS et al. The role of probiotics in the immune response and intestinal microbiota of children with celiac disease: a systematic review. Rev Paul Pediatr. 2021;40.
Sacchetti L, Nardelli C. Gut microbiome investigation in celiac disease: from methods to its pathogenetic role. Clin Chem Lab Med CCLM. 2020;58:340–9. https://doi.org/10.1515/cclm-2019-0657 .
doi: 10.1515/cclm-2019-0657
pubmed: 31494628
Pecora F, Persico F, Gismondi P, et al. Gut microbiota in celiac disease: is there any role for probiotics? Front Immunol. 2020;11:957.
doi: 10.3389/fimmu.2020.00957
pubmed: 32499787
pmcid: 7243837
De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:1–7.
doi: 10.1186/1471-2180-10-63
Conte M, Porpora M, Nigro F, et al. Pro-pre and postbiotic in celiac disease. Appl Sci. 2021. https://doi.org/10.3390/app11178185 .
doi: 10.3390/app11178185
Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152:552–8.
doi: 10.1111/j.1365-2249.2008.03635.x
pubmed: 18422736
pmcid: 2453197
Seiler CL, Kiflen M, Stefanolo JP, et al. Probiotics for celiac disease: a systematic review and meta-analysis of randomized controlled trials. Off J Am Coll Gastroenterol ACG. 2020;115:1584–95.
doi: 10.14309/ajg.0000000000000749
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898 .
doi: 10.1136/bmj.l4898
pubmed: 31462531
Harnett J, Myers S P, Rolfe M. Probiotics and the microbiome in celiac disease: a randomised controlled trial. Evid Based Complement Altern Med 2016. 2016.
Pinto-Sánchez MI, Smecuol EC, Temprano MP, et al. Bifidobacterium infantis NLS super strain reduces the expression of α-defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients. J Clin Gastroenterol. 2017;51:814–7.
doi: 10.1097/MCG.0000000000000687
pubmed: 27636409
Olivares M, Castillejo G, Varea V, Sanz Y. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. Br J Nutr. 2014;112:30–40.
doi: 10.1017/S0007114514000609
pubmed: 24774670
Primec M, Klemenak M, Di Gioia D, et al. Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-α and short-chain fatty acids. Clin Nutr. 2019;38:1373–81.
doi: 10.1016/j.clnu.2018.06.931
pubmed: 29960810
Quagliariello A, Aloisio I, Bozzi Cionci N, et al. Effect of Bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: a pilot study. Nutrients. 2016;8:660.
doi: 10.3390/nu8100660
pubmed: 27782071
pmcid: 5084046
Smecuol E, Hwang HJ, Sugai E, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol. 2013;47:139–47.
doi: 10.1097/MCG.0b013e31827759ac
pubmed: 23314670
Smecuol E, Constante M, Temprano MP, et al. Effect of Bifidobacterium infantis NLS super strain in symptomatic coeliac disease patients on long-term gluten-free diet–an exploratory study. Benef Microbes. 2020;11:527–34.
doi: 10.3920/BM2020.0016
pubmed: 33032471
Martinello F, Roman CF, Souza PAD. Effects of probiotic intake on intestinal bifidobacteria of celiac patients. Arq Gastroenterol. 2017;54:85–90.
doi: 10.1590/s0004-2803.201700000-07
pubmed: 28273274
Klemenak M, Dolinšek J, Langerholc T, Di Gioia D, Mičetić-Turk D. Administration of bifidobacterium breve decreases the production of TNF-α in children with celiac disease. Dig Dis Sci. 2015;60:3386–92.
doi: 10.1007/s10620-015-3769-7
pubmed: 26134988
Ali B, Khan AR. Efficacy of probiotics in management of celiac disease. Cureus. 2022;14.
Oscarsson E, Håkansson Å, Andrén Aronsson C, Molin G, Agardh D. Effects of probiotic bacteria Lactobacillaceae on the gut microbiota in children with celiac disease autoimmunity: a placebo-controlled and randomized clinical trial. Front Nutr. 2021;8:354.
doi: 10.3389/fnut.2021.680771
Håkansson Å, Andrén Aronsson C, Brundin C, Oscarsson E, Molin G, Agardh D. Effects of Lactobacillus plantarum and Lactobacillus paracasei on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. Nutrients. 2019;11:1925.
doi: 10.3390/nu11081925
pubmed: 31426299
pmcid: 6723580
Demiroren K. Can a synbiotic supplementation contribute to decreasing anti-tissue transglutaminase levels in children with potential celiac disease? Pediatr Gastroenterol Hepatol Nutr. 2020;23:397.
doi: 10.5223/pghn.2020.23.4.397
pubmed: 32704500
pmcid: 7354869
Aldaghi M-A, Dehghani S-M, Haghighat M. Evaluation of the correlation between tTG-IgA titer and duodenal biopsy findings in children with suspected celiac disease. Iran J Pediatr. 2016;26.
Kingstone K, Gillett HR, Johnston SD, Smye M. Lactulose-mannitol intestinal permeability test: a useful screening test for adult coeliac disease/Author’s reply. Ann Clin Biochem. 2001;38:415.
pubmed: 11471891
Chibbar R, Dieleman LA. The gut microbiota in celiac disease and probiotics. Nutrients. 2019. https://doi.org/10.3390/nu11102375 .
doi: 10.3390/nu11102375
pubmed: 31590358
pmcid: 6836185
Girbovan A, Sur G, Samasca G, Lupan I. Dysbiosis a risk factor for celiac disease. Med Microbiol Immunol. 2017;206:83–91. https://doi.org/10.1007/s00430-017-0496-z .
doi: 10.1007/s00430-017-0496-z
pubmed: 28204873